Skip to content
value.today

Mersana Therapeutics Inc.

Total raised
$70 M
4 rounds on record
Latest round
$33 M
Jun 2016
First round on record
Jul 2012
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Mersana Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2016$33 MNo. 4$10 to $50 million

Mersana Therapeutics Inc.: Raise no. 4, Jun 2016

Investors in this round

13 investors had bought by the notice of Jun 24, 2016: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Mersana Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$33 M of $33 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anna Protopapas · Executive Officer, Director
  • Donald Bergstrom · Executive Officer
  • Eva Jack · Executive Officer
  • Michael J. Kaufman · Executive Officer
  • Timothy Lowinger · Executive Officer
  • Wayne J. Foster · Executive Officer
  • David Mott · Director
  • Elaine J. Jones · Director
  • Sara J. Nayeem · Director
  • Thomas J. Beck · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Eva Jack, Chief business officer. Source: SEC Form D, newest notice filed Jun 24, 2016. Read the notice at the SEC.

equitySEC
Feb 2015$10 MNo. 3$10 to $50 million

Mersana Therapeutics Inc.: Raise no. 3, Feb 2015

Investors in this round

10 investors had bought by the notice of Mar 1, 2016: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Mersana Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $35 M offered; $25 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anna Protopapas · Executive Officer, Director
  • Donald Bergstrom · Executive Officer
  • Eva Jack · Executive Officer
  • Michael J. Kaufman · Executive Officer
  • Timothy Lowinger · Executive Officer
  • Wayne J. Foster · Executive Officer
  • David Mott · Director
  • Elaine J. Jones · Director
  • Sara J. Nayeem · Director
  • Thomas J. Beck · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Eva Jack, Chief business officer. Source: SEC Form D and 1 amendment, newest notice filed Mar 1, 2016. Read the notice at the SEC.

equitySEC
Sep 2013$15 MNo. 2$10 to $50 million

Mersana Therapeutics Inc.: Raise no. 2, Sep 2013

Investors in this round

10 investors had bought by the notice of Apr 8, 2014: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Mersana Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Mott · Executive Officer, Director
  • Donald Bergstrom · Executive Officer
  • Eva Jack · Executive Officer
  • Peter Park · Executive Officer
  • Timothy B. Lowinger · Executive Officer
  • Wayne B. Foster · Executive Officer
  • Nicholas G. Bacopoulos · Director
  • Sara Nayeem · Director
  • Thomas Beck · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Wayne Foster, Executive Vice President of Finance. Source: SEC Form D and 1 amendment, newest notice filed Apr 8, 2014. Read the notice at the SEC.

equity, optionsSEC
Jul 2012$13 MNo. 1$10 to $50 million

Mersana Therapeutics Inc.: Raise no. 1, Jul 2012

Investors in this round

12 investors had bought by the notice of Aug 9, 2012: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Mersana Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $27 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Burkhard B. Blank · Executive Officer
  • Michael G. Metzger · Executive Officer
  • Nicholas G. Bacopoulos · Executive Officer, Director
  • Timothy B. Lowinger · Executive Officer
  • David G. Mott · Director
  • Karen G. Hong · Director
  • Sara G. Nayeem · Director
  • Thomas G. Beck · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Metzger, Chief Operating Officer & Assistant Secretary & Treasurer. Source: SEC Form D, newest notice filed Aug 9, 2012. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Mersana Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2016).

    SEC Form D · Jun 2016

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2016

That is all the official record says: Mersana Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: the address on record now leads to another company's site.

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Mersana Therapeutics Inc.
InvestorKindAmountRoundRoleSource
Fmr LLCFund or asset managernot statednot statedHeld Series A-1 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Nea 14 GP, LTDCompanynot statednot statedHeld Series A-1, B-1 and C-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
NEA Partners 14, L.P.Fund or asset managernot statednot statedHeld Series A-1, B-1 and C-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
New Enterprise Associates 14, L.P.Fund or asset managernot statednot statedHeld Series A-1, B-1 and C-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 13 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Mersana Therapeutics Inc.
NameRoleNamed in
Anna ProtopapasExecutive officerJun 2016
Donald BergstromExecutive officerJun 2016
Eva JackExecutive officerJun 2016
Michael J. KaufmanExecutive officerJun 2016
Timothy LowingerExecutive officerJun 2016
Wayne J. FosterExecutive officerJun 2016
David MottExecutive officerMar 2015
Peter ParkExecutive officerMar 2015
Wayne FosterExecutive officerMar 2015
Timothy B. LowingerExecutive officerApr 2014
Wayne B. FosterExecutive officerApr 2014
Michael G. MetzgerExecutive officerOct 2013
Nicholas G. BacopoulosExecutive officerOct 2013
Peter G. ParkExecutive officerOct 2013
Burkhard B. BlankExecutive officerAug 2012
Anna ProtopapasDirectorJun 2016
David MottDirectorJun 2016
Elaine J. JonesDirectorJun 2016
Sara J. NayeemDirectorJun 2016
Thomas J. BeckDirectorJun 2016
Elaine JonesDirectorMar 2015
Sara NayeemDirectorMar 2015
Thomas BeckDirectorMar 2015
Nicholas G. BacopoulosDirectorApr 2014
David G. MottDirectorOct 2013
Sara G. NayeemDirectorOct 2013
Thomas G. BeckDirectorOct 2013
Karen G. HongDirectorAug 2012

About

Company in Cambridge, United States.